Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMYMP) EBIAT (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed EBIAT for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly EBIAT rose 1405.56% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 billion through Dec 2025, up 164.11% year-over-year, with the annual reading at $7.1 billion for FY2025, 178.83% up from the prior year.
  • EBIAT for Q4 2025 was $1.1 billion at Bristol Myers Squibb, down from $2.2 billion in the prior quarter.
  • The five-year high for EBIAT was $2.5 billion in Q1 2025, with the low at -$11.9 billion in Q1 2024.
  • Average EBIAT over 5 years is $783.4 million, with a median of $1.6 billion recorded in 2022.
  • The sharpest move saw EBIAT surged 25812.5% in 2023, then crashed 626.57% in 2024.
  • Over 5 years, EBIAT stood at $2.4 billion in 2021, then fell by 15.39% to $2.0 billion in 2022, then decreased by 11.46% to $1.8 billion in 2023, then plummeted by 95.95% to $72.0 million in 2024, then surged by 1405.56% to $1.1 billion in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at $1.1 billion, $2.2 billion, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.